Revuforj is the first so-called menin inhibitor cleared in the U.S., securing FDA approval for use in adults and certain ...

Researchers explain how a drug that helps patients with neurological issues walk may also provide a surprising boost for the ...

The U.S. patient population for Revuforj in its approved indication is roughly 2,000 according to Syndax. KMT2A leukemias ...

Fampridine is currently used to improve walking ability in multiple sclerosis. A new study shows that it could also help individuals with reduced ...

With the failure of AbbVie’s emraclidine in two mid-stage trials, Bristol Myers Squibb’s Cobenfy is 'sole muscarinic winner.' ...

"Severe neutropenia occurs in a small percentage of patients taking clozapine; however, neutropenia is associated with an ...

The U.S. Food and Drug Administration on Friday approved Syndax Pharmaceuticals' drug for the treatment of adult and ...

The third-quarter earnings season came to an end this week for large drugmakers, with AstraZeneca AZN and Bayer BAYRY ...

The U.S. Food and Drug Administration has approved Bristol Myers Squibb's Cobenfy (xanomeline and trospium chloride), a first ...

The Company reported a net loss of approximately $8.4 million, or $0.25 per share, for the three months ended September 30, ...

Aging brings many changes that can be unpleasant, from losing mobility to needing help with tasks that used to be easy. For those with Alzheimer's disease and other forms of ...

The FDA added a warning to the label of esketamine nasal spray (Spravato), noting that long-term cognitive and memory ...